Anavex Life Sciences Corp (AVXL)

[georgejjl]

AF710B (aka ANAVEX 3-71),is a brain-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications.

https://iibr.gov.il/Research_Development/PatentsAndApplications/Pages/AF710B.aspx

AF710B is effective against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and has also demonstrated beneficial effects on neuroinflammation and mitochondrial dysfunctions1.

Similarly, AF710B lon?g-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in McGill-R-Thy1-APP transgenic rats2. These effects were accompanied by reductions in amyloid pathology and markers of neuroinflammation and increases in amyloid cerebrospinal fluid clearance and levels of a synaptic marker. ??

With long-lasting disease-modifying properties at low dose, AF710B is a promising novel therapeutic agent for treating Alzheimer's and other related diseases.

AF710B (ANAVEX 3-71) and its patents were licensed for further development. U.S. FDA Granted Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia.

AF710B, a Novel M1/s1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease. Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, Brandeis R, Elkon H, Nahum V, Gershonov E, LaFerla FM, Medeiros R. Neurodegener Dis. 2016;16(1-2):95-110;


https://www.karger.com/Article/Pdf/440864